sibutramine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2440 106650-56-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sibutramine
  • (+/-)-Sibutramine
  • didemethyl sibutramine hydrochloride
  • racemic sibutramine
  • sibutramine hydrochloride
  • sibutramine hydrochloride hydrate
  • BTS 54524
  • didemethyl sibutramine HCl
  • sibutramine HCl
  • didesmethylsibutramine
serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
  • Molecular weight: 279.85
  • Formula: C17H26ClN
  • CLOGP: 5.59
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -5.47
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.90 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.77 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Nov. 22, 1997 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A08AA10 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
FDA MoA N0000000114 Dopamine Uptake Inhibitors
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175424 Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D001067 Appetite Depressants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:50949 SSRI
CHEBI has role CHEBI:74518 anti-obestic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Obesity indication 414916001 DOID:9970
Tachyarrhythmia contraindication 6285003
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Bulimia nervosa contraindication 78004001
Chronic renal failure syndrome contraindication 90688005
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Transient ischemic attack contraindication 266257000 DOID:224
Serotonin syndrome contraindication 371089000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Peripheral arterial occlusive disease contraindication 399957001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.18 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.53 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 5.26 WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 6.03 WOMBAT-PK CHEMBL
Alpha-2C adrenergic receptor GPCR WOMBAT-PK
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 4.70 WOMBAT-PK
Cytochrome P450 2B6 Enzyme INHIBITOR IC50 5.79 IUPHAR
Solute carrier family 22 member 2 Transporter IC50 4.54 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 5.96 DRUG MATRIX
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 4.70 IUPHAR

External reference:

IDSource
4024106 VUID
N0000022111 NUI
D02571 KEGG_DRUG
125494-59-9 SECONDARY_CAS_RN
4021089 VANDF
4024106 VANDF
C0074493 UMLSCUI
CHEBI:9137 CHEBI
CHEMBL1419 ChEMBL_ID
DB01105 DRUGBANK_ID
CHEMBL3989830 ChEMBL_ID
CHEMBL1200765 ChEMBL_ID
C058254 MESH_SUPPLEMENTAL_RECORD_UI
5210 PUBCHEM_CID
2586 IUPHAR_LIGAND_ID
6124 INN_ID
84467-54-9 SECONDARY_CAS_RN
WV5EC51866 UNII
1294535 RXNORM
d04260 MMSL
007298 NDDF
108373009 SNOMEDCT_US
386838007 SNOMEDCT_US
783113003 SNOMEDCT_US

Pharmaceutical products:

None